Our Press Releases | Association for Accessible Medicines

GRx+Biosims - No-cost FDA workshop limited to first 100 who sign up. Act now!

Oct 16, 2019 | Rachel Schwartz

AAM Reaction to FDA Statement on Patient Access to Generic Drugs

California State Capitol - AB 824

Oct 8, 2019 | Rachel Schwartz

AAM Response to CA Governor Newsom Signing AB 824

Sep 20, 2019 | Rachel Schwartz

Seniors Denied Access to New, Lower-Priced Generic Drugs Due to Medicare Coverage Delays

Jul 23, 2019 | Rachel Schwartz

AAM Applauds Senate Finance’s Meaningful Effort to Reduce Drug Prices for America’s Patients

Jul 2, 2019 | Rachel Schwartz

National Survey Finds Significant Voter Opposition to Patent Settlement Legislation

Biosimilars

Jun 26, 2019 | Rachel Schwartz

AAM Applauds Sens. Cornyn and Blumenthal’s Efforts to Accelerate Access to More Affordable Biosimilar Medicines

Jun 26, 2019 | Jewel Smith

AAM Announces New 2019 Members

May 23, 2019 | Rachel Schwartz

AAM Statement on FTC Report on Patent Settlements

May 21, 2019 | Rachel Schwartz

AAM Statement on House Bills 965, 1499 and 938

May 17, 2019 | Rachel Schwartz

AAM Statement on the Importance of Generic and Biosimilar Quality and Robust Competition

May 16, 2019 | Rachel Schwartz

How Generic Drug Makers Are Responding to Price-Fixing Lawsuit

May 13, 2019 | Rachel Schwartz

The 11th Annual Edition of AAM Access & Savings Report Finds Generic Savings Totaled $293 Billion in 2018